Press Releases

Date Title and Summary View
Toggle Summary MediWound to Participate in Upcoming March Investment Conferences
YAVNE, Israel , Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
Fourth Quarter Revenues of $6.7 Million   - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million   - Product Revenue Up 117% Conference call begins today at 8:30 am ET   YAVNE, Israel , Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company
View HTML
Toggle Summary MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 An Investigator-Initiated Trial Will Run in Parallel YAVNE, Israel , Feb. 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical
View HTML
Toggle Summary MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
YAVNE, Israel , Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , Chief Executive Officer, will participate in a
View HTML
Toggle Summary MediWound Provides Progress Update on Its EscharEx Clinical Development Program
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Protocol Submitted to FDA for Pharmacology Clinical Study with Data Expected in Second Half 2021 YAVNE, Israel , Jan.
View HTML
Toggle Summary MediWound to Participate in Upcoming Investor Conferences in January
YAVNE, Israel , Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10 th
View HTML
Toggle Summary Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
Data to be Published in a Peer-Reviewed Journal in First Half 2021 YAVNE, Israel , Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced
View HTML
Toggle Summary MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
YAVNE, Israel , Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid ® global presence and entered
View HTML
Toggle Summary MediWound Reports Third Quarter 2020 Financial Results
Total Third Quarter R evenues of $6.6   Million Increased 29 % Y ear-over- Y ear Assigned PDUFA Goal Date of June 29, 2021   for NexoBrid BLA YAVNE, Israel , Nov. 10, 2020 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies
View HTML